We are live on ! Find out more
FCMI

Foresite Capital Management III Portfolio holdings

AUM $37.9M
1-Year Est. Return 6.87%
This Fund
S&P 500
This Quarter Est. Return
+22.06%
1 Year Est. Return
-6.87%
3 Year Est. Return
+444.07%
5 Year Est. Return
+547.28%
10 Year Est. Return
–
AUM
$464M
AUM Growth
+$5.56M
Cap. Flow
-$35.8M
Cap. Flow %
-7.71%
Top 10 Hldgs %
82.23%
Holding
26
New
2
Increased
2
Reduced
9
Closed
2

Top Buys

Rank Stock Value
1
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$1.85M
2
AKAO
Achaogen Inc
AKAO
+$297K

Top Sells

Rank Stock Value
1
AERI
Aerie Pharmaceuticals
AERI
+$13.6M
2
BPMC
Blueprint Medicines
BPMC
+$11.9M
3
ASND icon
Ascendis Pharma A/S
ASND
+$7.26M
4
IMMU
Immunomedics Inc
IMMU
+$3.18M
5
AIMT
Aimmune Therapeutics
AIMT
+$2.56M

Sector Composition

Rank Sector Weight
1 Healthcare 50.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AERI
1
DELISTED
Aerie Pharmaceuticals
AERI
$115M 24.85%
1,708,046
-242,431
-12% -$13.6M
IMMU
2
DELISTED
Immunomedics Inc
IMMU
$60.2M 12.96%
2,541,729
-158,271
-6% -$3.18M
ALDR
3
DELISTED
Alder Biopharmaceuticals
ALDR
$46.5M 10.01%
2,942,130
– –
RCUS icon
4
Arcus Biosciences
RCUS
$3.39B
$42.2M 9.08%
3,445,461
– –
AKAO
5
DELISTED
Achaogen Inc
AKAO
$24.9M 5.36%
2,874,418
+24,418
+0.9% +$297K
AIMT
6
DELISTED
Aimmune Therapeutics
AIMT
$22.9M 4.93%
851,213
-83,807
-9% -$2.56M
CBAY
7
DELISTED
Cymabay Therapeutics
CBAY
$21M 4.51%
1,562,040
– –
MYOK
8
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$19.5M 4.2%
392,789
– –
BPMC
9
DELISTED
Blueprint Medicines
BPMC
$15.9M 3.42%
250,000
-150,000
-38% -$11.9M
XLRN
10
DELISTED
Acceleron Pharma
XLRN
$13.5M 2.91%
278,753
– –
EPZM
11
DELISTED
Epizyme, Inc
EPZM
$12.7M 2.74%
940,685
-57,593
-6% -$896K
ASND icon
12
Ascendis Pharma A/S
ASND
$16.3B
$12.7M 2.74%
191,588
-110,421
-37% -$7.26M
BOLD
13
DELISTED
Audentes Therapeutics, Inc
BOLD
$12M 2.59%
315,331
– –
SLDB icon
14
Solid Biosciences
SLDB
$776M
$12M 2.59%
22,526
– –
VRNA
15
DELISTED
Verona Pharma
VRNA
$6.87M 1.48%
502,825
-62,467
-11% -$1.05M
ACRS icon
16
Aclaris Therapeutics
ACRS
$737M
$6.24M 1.34%
312,368
– –
BHVN
17
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$4.18M 0.9%
105,706
– –
SGMO
18
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$3.77M 0.81%
265,605
+111,143
+72% +$1.85M
IMMU
19
CALL
DELISTED
Immunomedics Inc
IMMU
$3.55M 0.76%
+150,000
New +$3.01M
IMMU
20
PUT
DELISTED
Immunomedics Inc
IMMU
$3.55M 0.76%
+150,000
New +$3.01M
WVE icon
21
Wave Life Sciences
WVE
$1.13B
$2.87M 0.62%
75,000
– –
FBRX icon
22
Forte Biosciences
FBRX
$1.57B
$1.39M 0.3%
396
– –
ARDX icon
23
Ardelyx
ARDX
$1.25B
$482K 0.1%
130,304
-73,288
-36% -$340K
BDSI
24
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$58K 0.01%
19,500
-130,504
-87% -$309K
RARX
25
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
– –
-50,000
Closed -$266K
1
2

Similar funds

PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
KCGDR
Kiron Capital Gestao de Recursos Sao Paulo, Brazil $36.9M AUM 49.85% 1-Year Est. Return
SEM
Spectrum Equity Management San Francisco, California $39.1M AUM 63.69% 1-Year Est. Return
ALFIA
Accel Leaders Fund II Associates Palo Alto, California $36.6M AUM 58.14% 1-Year Est. Return
MCMI
Matrix China Management III Grand Cayman, Cayman Islands $39.3M AUM
LCM
LH Capital Markets New York $39.4M AUM 14.61% 1-Year Est. Return
HLC
Hunt Lane Capital New York $39.6M AUM 58.74% 1-Year Est. Return
KXA
KPCB XV Associates Menlo Park, California $35.8M AUM 57.59% 1-Year Est. Return

Foresite Capital Management III's Q2 2018 Portfolio in Review

As of Q2 2018, Foresite Capital Management III held 26 positions worth $464M, up 1.2% from $459M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Foresite Capital Management III withdrew a net $35.8M in Q2 2018, closing 2 positions and reducing 9 holdings. Its most notable exit was Ra Pharmaceuticals, Inc. Common Stock, an estimated $266K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 50% of assets, down from 53% a quarter earlier.

Against the trend, Foresite Capital Management III added an estimated $1.85M to SANGAMO THERAPEUTICS INC.

  • Foresite Capital Management III added most to SANGAMO THERAPEUTICS INC in Q2 2018, an estimated $1.85M increase.
  • Foresite Capital Management III's biggest Q2 2018 reduction was Aerie Pharmaceuticals, cutting an estimated $13.6M.
  • Foresite Capital Management III fully exited Ra Pharmaceuticals, Inc. Common Stock in Q2 2018, selling an estimated $266K.
  • Foresite Capital Management III's ten largest holdings make up 82% of its $464M portfolio in Q2 2018.
  • Foresite Capital Management III opened 2 new positions and closed 2 in Q2 2018.
  • Foresite Capital Management III's portfolio value rose 1.2% quarter-over-quarter to $464M.

Based on Foresite Capital Management III's 13F filing for Q2 2018, filed 14 Aug 2018.